[18F]FDG-PET/CT in Staphylococcus aureus bacteremia: a systematic review

D T P Buis; E Sieswerda; I J E Kouijzer; W Y Huynh; G L Burchell; M A H Berrevoets; J M Prins; K C E Sigaloff

doi:10.1186/s12879-022-07273-x

[18F]FDG-PET/CT in Staphylococcus aureus bacteremia: a systematic review

D T P Buis, E Sieswerda, I J E Kouijzer, W Y Huynh, G L Burchell, M A H Berrevoets, J M Prins, K C E Sigaloff

Research output: Contribution to journal › Article › Academic › peer-review

12 Downloads (Pure)

Abstract

OBJECTIVES: [18F]FDG-PET/CT is used for diagnosing metastatic infections in Staphylococcus aureus bacteremia (SAB) and guidance of antibiotic treatment. The impact of [18F]FDG-PET/CT on outcomes remains to be determined. The aim of this systematic review was to summarize the effects of [18F]FDG-PET/CT on all-cause mortality and new diagnostic findingsin SAB.

METHODS: We systematically searched PubMed, EMBASE.com, Web of Science, and Wiley's Cochrane library from inception to 29 January 2021. Eligible studies were randomized controlled trials, clinically controlled trials, prospective and retrospective cohort studies, and case-control studies investigating the effects of [18F]FDG-PET/CT in hospitalized adult patients with SAB. We excluded studies lacking a control group without [18F]FDG-PET/CT. Risk of bias was assessed using the ROBINS-I tool and certainty of evidence using the GRADE approach by two independent reviewers.

RESULTS: We identified 1956 studies, of which five were included in our qualitative synthesis, including a total of 880 SAB patients. All studies were non-randomized and at moderate or serious risk of bias. Four studies, including a total of 804 patients, reported lower mortality in SAB patients that underwent [18F]FDG-PET/CT. One study including 102 patients reported more detected metastatic foci in the participants in whom [18F]FDG-PET/CT was performed.

DISCUSSION: We found low certainty of evidence that [18F]FDG-PET/CT reduces mortality in patients with SAB. This effect is possibly explained by a higher frequency of findings guiding optimal antibiotic treatment and source control interventions.

Original language	English
Article number	282
Pages (from-to)	1-10
Journal	BMC Infectious Diseases
Volume	22
Issue number	1
DOIs	https://doi.org/10.1186/s12879-022-07273-x
Publication status	Published - Mar 2022

Keywords

Bacteremia
Staphylococcus aureus
Systematic review
[18F]FDG-PET/CT

Access to Document

10.1186/s12879-022-07273-xLicence: CC BY

s12879-022-07273-xFinal published version, 1.77 MBLicence: CC BY

Cite this

@article{a5c20c8258c4475ba0b96f2ee2b20eb4,

title = "[18F]FDG-PET/CT in Staphylococcus aureus bacteremia: a systematic review",

abstract = "OBJECTIVES: [18F]FDG-PET/CT is used for diagnosing metastatic infections in Staphylococcus aureus bacteremia (SAB) and guidance of antibiotic treatment. The impact of [18F]FDG-PET/CT on outcomes remains to be determined. The aim of this systematic review was to summarize the effects of [18F]FDG-PET/CT on all-cause mortality and new diagnostic findingsin SAB.METHODS: We systematically searched PubMed, EMBASE.com, Web of Science, and Wiley's Cochrane library from inception to 29 January 2021. Eligible studies were randomized controlled trials, clinically controlled trials, prospective and retrospective cohort studies, and case-control studies investigating the effects of [18F]FDG-PET/CT in hospitalized adult patients with SAB. We excluded studies lacking a control group without [18F]FDG-PET/CT. Risk of bias was assessed using the ROBINS-I tool and certainty of evidence using the GRADE approach by two independent reviewers.RESULTS: We identified 1956 studies, of which five were included in our qualitative synthesis, including a total of 880 SAB patients. All studies were non-randomized and at moderate or serious risk of bias. Four studies, including a total of 804 patients, reported lower mortality in SAB patients that underwent [18F]FDG-PET/CT. One study including 102 patients reported more detected metastatic foci in the participants in whom [18F]FDG-PET/CT was performed.DISCUSSION: We found low certainty of evidence that [18F]FDG-PET/CT reduces mortality in patients with SAB. This effect is possibly explained by a higher frequency of findings guiding optimal antibiotic treatment and source control interventions.",

keywords = "Bacteremia, Staphylococcus aureus, Systematic review, [18F]FDG-PET/CT",

author = "Buis, {D T P} and E Sieswerda and Kouijzer, {I J E} and Huynh, {W Y} and Burchell, {G L} and Berrevoets, {M A H} and Prins, {J M} and Sigaloff, {K C E}",

note = "Publisher Copyright: {\textcopyright} 2022. The Author(s).",

year = "2022",

month = mar,

doi = "10.1186/s12879-022-07273-x",

language = "English",

volume = "22",

pages = "1--10",

journal = "BMC Infectious Diseases",

issn = "1471-2334",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - [18F]FDG-PET/CT in Staphylococcus aureus bacteremia

T2 - a systematic review

AU - Buis, D T P

AU - Sieswerda, E

AU - Kouijzer, I J E

AU - Huynh, W Y

AU - Burchell, G L

AU - Berrevoets, M A H

AU - Prins, J M

AU - Sigaloff, K C E

PY - 2022/3

Y1 - 2022/3

N2 - OBJECTIVES: [18F]FDG-PET/CT is used for diagnosing metastatic infections in Staphylococcus aureus bacteremia (SAB) and guidance of antibiotic treatment. The impact of [18F]FDG-PET/CT on outcomes remains to be determined. The aim of this systematic review was to summarize the effects of [18F]FDG-PET/CT on all-cause mortality and new diagnostic findingsin SAB.METHODS: We systematically searched PubMed, EMBASE.com, Web of Science, and Wiley's Cochrane library from inception to 29 January 2021. Eligible studies were randomized controlled trials, clinically controlled trials, prospective and retrospective cohort studies, and case-control studies investigating the effects of [18F]FDG-PET/CT in hospitalized adult patients with SAB. We excluded studies lacking a control group without [18F]FDG-PET/CT. Risk of bias was assessed using the ROBINS-I tool and certainty of evidence using the GRADE approach by two independent reviewers.RESULTS: We identified 1956 studies, of which five were included in our qualitative synthesis, including a total of 880 SAB patients. All studies were non-randomized and at moderate or serious risk of bias. Four studies, including a total of 804 patients, reported lower mortality in SAB patients that underwent [18F]FDG-PET/CT. One study including 102 patients reported more detected metastatic foci in the participants in whom [18F]FDG-PET/CT was performed.DISCUSSION: We found low certainty of evidence that [18F]FDG-PET/CT reduces mortality in patients with SAB. This effect is possibly explained by a higher frequency of findings guiding optimal antibiotic treatment and source control interventions.

AB - OBJECTIVES: [18F]FDG-PET/CT is used for diagnosing metastatic infections in Staphylococcus aureus bacteremia (SAB) and guidance of antibiotic treatment. The impact of [18F]FDG-PET/CT on outcomes remains to be determined. The aim of this systematic review was to summarize the effects of [18F]FDG-PET/CT on all-cause mortality and new diagnostic findingsin SAB.METHODS: We systematically searched PubMed, EMBASE.com, Web of Science, and Wiley's Cochrane library from inception to 29 January 2021. Eligible studies were randomized controlled trials, clinically controlled trials, prospective and retrospective cohort studies, and case-control studies investigating the effects of [18F]FDG-PET/CT in hospitalized adult patients with SAB. We excluded studies lacking a control group without [18F]FDG-PET/CT. Risk of bias was assessed using the ROBINS-I tool and certainty of evidence using the GRADE approach by two independent reviewers.RESULTS: We identified 1956 studies, of which five were included in our qualitative synthesis, including a total of 880 SAB patients. All studies were non-randomized and at moderate or serious risk of bias. Four studies, including a total of 804 patients, reported lower mortality in SAB patients that underwent [18F]FDG-PET/CT. One study including 102 patients reported more detected metastatic foci in the participants in whom [18F]FDG-PET/CT was performed.DISCUSSION: We found low certainty of evidence that [18F]FDG-PET/CT reduces mortality in patients with SAB. This effect is possibly explained by a higher frequency of findings guiding optimal antibiotic treatment and source control interventions.

KW - Bacteremia

KW - Staphylococcus aureus

KW - Systematic review

KW - [18F]FDG-PET/CT

UR - http://www.scopus.com/inward/record.url?scp=85127062654&partnerID=8YFLogxK

U2 - 10.1186/s12879-022-07273-x

DO - 10.1186/s12879-022-07273-x

M3 - Article

C2 - 35331165

SN - 1471-2334

VL - 22

SP - 1

EP - 10

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

IS - 1

M1 - 282

ER -

[18F]FDG-PET/CT in Staphylococcus aureus bacteremia: a systematic review

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this